Jacobio Pharma Presents Clinical Results of Glecirasib in Combination with JAB-3312 at ESMO ...Middle East

PR Newswire - News
The ORR (objective response rate) and the DCR (disease control rate) in the frontline setting of glecirasib (KRAS G12C Inhibitor) in combination with JAB-3312 (SHP2 inhibitor) were 65.5% (38/58) and 100% respectively in all dose groups of advanced non-small cell lung cancer (NSCLC), among...

Hence then, the article about jacobio pharma presents clinical results of glecirasib in combination with jab 3312 at esmo was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Jacobio Pharma Presents Clinical Results of Glecirasib in Combination with JAB-3312 at ESMO )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News